Disc Medicine, Inc. (NASDAQ: IRON) had its price target raised by analysts at HC Wainwright from $70.00 to $118.00. They now have a "buy" rating on the stock.
Disc Medicine to Participate in Upcoming Investor Conferences
Disc Medicine, Inc. (NASDAQ: IRON) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $83.00 price target on the stock, up previously from $75.00.
Disc Medicine Reports Third Quarter 2024 Financial Results and Provides Business Update
Disc Medicine Secures $200 Million in Non-Dilutive Debt Financing from Hercules Capital, Inc. [Yahoo! Finance]